期刊
INTERNATIONAL JOURNAL OF OBESITY
卷 37, 期 5, 页码 699-703出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/ijo.2012.116
关键词
adipose tissue; endocannabinoids; non-alcoholic fatty liver disease; rimonabant
资金
- Academy of Finland
- Sigrid Juselius Foundation
- Novo Nordisk Foundation
- European Commission [LSHM-CT2005-018734]
OBJECTIVE: Studies in mice have suggested that endocannabinoid blockade using the cannabinoid receptor type 1 (CB1) blocker rimonabant prevents obesity-induced hepatic steatosis. DESIGN AND SUBJECTS: To determine effects of rimonabant on liver fat in humans, we measured liver fat content by proton magnetic resonance spectroscopy in 37 subjects who used either a CB1 blocker rimonabant or placebo in a double-blind, randomized manner. This was retrospectively compared with a historical hypocaloric diet weight loss group (n=23). RESULTS: Weight loss averaged 8.5 +/- 1.4 kg in the rimonabant, 1.7 +/- 1.0 kg in the placebo and 7.5 +/- 0.2 kg in the hypocaloric diet group (P < 0.001, rimonabant vs placebo; NS, rimonabant vs hypocaloric diet). Liver fat decreased more in the rimonabant (5.9% (2.5-14.6%) vs 1.8% (0.9-3.5%), before vs after) than in the placebo group (6.8% (2.2-15.7%) vs 4.9% (1.6-7.8%), before vs after, P < 0.05). The percentage change in body weight correlated closely with the percentage loss of liver fat (r=0.70, P > 0.0001). The decreases in liver fat were comparable between the rimonabant and the young historical hypocaloric diet groups. CONCLUSIONS: We conclude that, unlike in mice, in humans rimonabant decreases liver fat in proportion to weight loss.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据